Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
TCT 25: VICTORY Trial: Intravascular Lithotripsy vs Super-High-Pressure Balloons for Calcified Coronary Lesions
Author(s): Matthias Bossard Added: 2 weeks ago
TCT 2025 - The randomized VICTORY Study finds OCT-guided PCI involving lesion preparation with the OPN super-high-pressure non-compliant balloon is non-inferior to intravascular lithotropsy.Dr Matthias Bossard (Kantonsspital Lucerne, Lucerne, CH) joins us to discuss findings from the VICTORY Trial, a randomized, multicenter, non-inferiority comparison evaluating intravascular lithotripsy versus… View more

Intervention

MI/ACS
AHA 25: Lp(a) and ASCVD: Translating Causal Evidence into Clinical Practice
Author(s): Michelle O'Donoghue Added: 3 days ago
AHA Scientific Sessions 2025 - Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) joins us to discuss the evolving understanding of the causal relationship between elevated lipoprotein(a) and atherosclerotic cardiovascular disease, and what this means for risk stratification and management strategies in clinical practice.Dr O'Donoghue begins by highlighting the importance for clinicians to… View more

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
ESC 25: LipoaScreen: Cascade Screening for LP(a)
Author(s): Jonas Brinck Added: 2 months ago
ESC Congress 2025 - Cascade screening proves to be an effective tool to identify more patients with elevated LP(a) levels.Dr Jonas Brinck (Karolinska Institute, SE) joins us to discuss findings from the LipoaScreen study, evaluating cascade screening for elevated lipoprotein(a) in relatives of patients with atherosclerotic coronary artery disease.This prospective study examined whether elevated… View more

Imaging & Diagnostics

Prevention & Chronic Conditions
CardioNerds @AHA23: An Extended Duration Short-Interfering RNA Targeting Lp(a)
Author(s): Steven E Nissen , Maryam Barkhordarian Added: 1 year ago
AHA 2023 — Investigator, Dr Steven E Nissen (Cleveland Clinic, US) is interviewed by CardioNerds Medical Education Fellow, Dr Maryam Barkhordarian (HMH Palisades Medical Center, US) on the trial that assessed the efficacy and safety of lepodisiran, a small interfering RNA (NCT05565742).The main purpose of this phase 2, randomised, double-blind, placebo-controlled study (Eli Lilly and Company) is… View more

Heart Failure

Prevention & Chronic Conditions
AHA 24: The ALPACAR Trial
Author(s): Steven E Nissen Added: 11 months ago
AHA Conference 2024 - Safety and efficacy outcomes of zerlasiran (Silence Therapeutics) in adults with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events (ASCVD).Dr Steven Nissen (Cleveland Clinic, US) joins us onsite at AHA Conference to discuss the findings from ALPACAR (NCT05537571).ALPACAR is a phase 2, randomized, five-arm, placebo-controlled trial… View more

Prevention & Chronic Conditions
AHA 24: The KRAKEN Trial
Author(s): Stephen Nicholls Added: 11 months ago
AHA Conference 2024 - Safety and efficacy outcomes of muvalaplin (Eli Lilly and Company) in adults with elevated lipoprotein(a) at high risk for cardiovascular events.Dr Stephen Nicholls (Monash University and The Victorian Heart Hospital, Melbourne, AU) joins us onsite at AHA Conference to discuss the findings from KRAKEN (NCT05563246).KRAKEN is a phase 2, randomized, placebo-controlled trial… View more

Prevention & Chronic Conditions
Findings from an Apolipoprotein B-Based Genetic Analysis
Added: 1 year ago Source:  Radcliffe Cardiology
AUTHOR: Brad WilsonIn a study published in the Journal of the American College of Cardiology (JACC), Dr Elias Björnson and his colleagues demonstrated that lipoprotein(a) (Lp(a)) is approximately six times more atherogenic than low-density lipoprotein (LDL) per particle.Lp(a) is a lipoprotein particle that has long been recognised as a causal factor for coronary heart disease (CHD). However,… View more
ESC 25: The HI-PRO Trial
Author(s): Gregory Piazza Added: 2 months ago
ESC Congress 2025 - HI-PRO shows apixaban 2.5mg twice daily reduced the risk of symptomatic recurrent venous thromboembolism when compared to placebo at 12 months.Dr Gregory Piazza (Brigham and Women's Hospital, US) joins us to discuss findings from the HI-PRO trial, evaluating extended-duration low-intensity apixaban versus placebo for secondary prevention in high-risk patients with provoked… View more

Anticoagulation

Vascular Disease and Surgery
ESC 25: The KARDIA-3 Study
Author(s): Neha Pagidipati Added: 2 months ago
ESC Congress 2025 - KARDIA 3 finds that a single dose of zilebesiran 300mg reduced office systolic blood pressure at month three compared to placebo, informing the dose, design and patient population for the upcoming zilebesiran phase III Cardiovascular outcomes trial.Dr Neha Pagidipati (Duke University Medical Center, US) joins us to discuss findings from the KARDIA-3 trial, evaluating… View more

Prevention & Chronic Conditions
ACC 25: The SMART-CHOICE 3 Trial
Author(s): Joo-Yong Hahn Added: 7 months ago
ACC 25 - SMART-CHOICE 3 Trial finds clopidogrel monotherapy to be the optimal anti-thrombotic strategy in high risk patients with contemporary drug-eluting stents.Dr Joo-Yong Hahn (Samsung Medical Center, Seoul, KR) joins us onsite at ACC Conference 2025 to discuss the findings from the SMART-CHOICE 3 study (NCT04418479). The study aims to evaluate the efficacy and safety of clopidogrel… View more

Anticoagulation

Intervention